EP0904069A4 - Pla2 inhibitoren von angiogenese - Google Patents

Pla2 inhibitoren von angiogenese

Info

Publication number
EP0904069A4
EP0904069A4 EP97917625A EP97917625A EP0904069A4 EP 0904069 A4 EP0904069 A4 EP 0904069A4 EP 97917625 A EP97917625 A EP 97917625A EP 97917625 A EP97917625 A EP 97917625A EP 0904069 A4 EP0904069 A4 EP 0904069A4
Authority
EP
European Patent Office
Prior art keywords
angiogenesis
pla2 inhibitors
pla2
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97917625A
Other languages
English (en)
French (fr)
Other versions
EP0904069A1 (de
Inventor
Jeffrey A Jackson
James D Winkler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0904069A1 publication Critical patent/EP0904069A1/de
Publication of EP0904069A4 publication Critical patent/EP0904069A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP97917625A 1996-03-26 1997-03-26 Pla2 inhibitoren von angiogenese Withdrawn EP0904069A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1424496P 1996-03-26 1996-03-26
US14244P 1996-03-26
PCT/US1997/004876 WO1997035567A1 (en) 1996-03-26 1997-03-26 Pla2 inhibitors of angiogenesis

Publications (2)

Publication Number Publication Date
EP0904069A1 EP0904069A1 (de) 1999-03-31
EP0904069A4 true EP0904069A4 (de) 2006-08-23

Family

ID=21764322

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97917625A Withdrawn EP0904069A4 (de) 1996-03-26 1997-03-26 Pla2 inhibitoren von angiogenese

Country Status (3)

Country Link
EP (1) EP0904069A4 (de)
JP (1) JP2000507946A (de)
WO (1) WO1997035567A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058126A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000649A1 (en) * 1993-06-25 1995-01-05 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
WO1995033461A1 (en) * 1994-06-02 1995-12-14 Smithkline Beecham Corporation Anti-inflammatory compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600840A (en) * 1978-05-30 1981-10-21 Wellcome Found Diphenylether derivatives useful as flukicidal agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000649A1 (en) * 1993-06-25 1995-01-05 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
WO1995033461A1 (en) * 1994-06-02 1995-12-14 Smithkline Beecham Corporation Anti-inflammatory compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9735567A1 *

Also Published As

Publication number Publication date
WO1997035567A1 (en) 1997-10-02
EP0904069A1 (de) 1999-03-31
JP2000507946A (ja) 2000-06-27

Similar Documents

Publication Publication Date Title
PL331856A1 (en) Heterocyclic inhibitors of metaloprotease
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
EP0984692A4 (de) Angiogenese-inhibitoren
EP1017682A4 (de) Neue angiogenese-inhibitoren
AP9701054A0 (en) Inhibitors of cycteine protease
PL327569A1 (en) Promedications of thrombosin inhibitors
PL329875A1 (en) Derivatives of carbolin
PL329195A1 (en) Derivatives of 6-phenylpyridol-2-amine
HU9603475D0 (en) Inhibitors of interlaukin-1beta converting enzyme
PL331338A1 (en) Thiosulphonamidic metaloprotease inhibitors
HUP9902099A3 (en) Methods and compositions useful for inhibition of angiogenesis
AU1740900A (en) Method of inhibiting angiogenesis
AU1271297A (en) Inhibitor of ceramidase
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
PL316669A1 (en) Angiogenesis inhibitors
PL327998A1 (en) Novel derivatives of 19-nor-pregnene
EP1005343A4 (de) Verwendung von csaids als inhibitoren der angiogenese
PL326863A1 (en) Thrombine inhibitors
PL328665A1 (en) Inhibitors of serinic protease
PL334975A1 (en) Application of gasto-intestinal lipase inhibitors
PL331803A1 (en) Bidonoric metaloprotease inhibitors
PL337725A1 (en) Inhibitors of proteases
AU2277597A (en) New inhibitors of sh2-mediated processes
HU9702480D0 (en) New polymorphe modification of doxazosin-mesylate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20060725

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19971229